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ABSTRACT
Nowadays, the metagenomic approach has been a very important tool in the 
discovery of new viruses in environmental and biological samples. Here we 
discuss how these discoveries may help to elucidate the etiology of diseases 
and the criteria necessary to establish a causal association between a virus 
and a disease.
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RESUMO
A abordagem metagenômica tem sido ferramenta muito importante 
atualmente na descoberta de novos vírus em amostras ambientais e biológicas. 
Aqui discutimos a maneira como essas descobertas podem ajudar a elucidar 
a etiologia de doenças e os critérios necessários para que a associação causal 
entre um vírus e uma doença seja estabelecida.
DESCRITORES: Metagenômica. Vírus. Virologia. Doenças 
Transmissíveis, etiologia. Causalidade. Postulados de Koch.
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Before the association between an infectious agent 
and a disease is made public, it needs to be well estab-
lished. The adequate treatment of patients suffering 
from an infectious disease, implementation of preven-
tive measures, understanding of the different phases 
of the disease, development of therapies, and occa-
sionally, the development of a vaccine depend on 
the elucidation of this association.13 The criteria for 
achieving correct associations are being proposed by 
eminent scientists.7,9-11,13,16,19
With regard to viruses, which are the focus here, the 
need for establishing a causal association is a very 
contemporary subject because many viruses are now 
being discovered. Metagenomic techniques and next-
generation sequencing platforms are the main drivers 
of these discoveries. At the same time, several poten-
tially infectious diseases and several cases of common 
infectious diseases, including acute respiratory disease, 
encephalitis, acute gastroenteritis, and hepatitis, do not 
have a known etiological agent.12,16
CRITERIA FOR CAUSAL ASSOCIATION 
BETWEEN AGENTS AND DISEASES
In the end of the 19th century, Koch11 defended the 
fundamental principles that helped establish the causal 
association between microorganisms and infectious 
diseases according to a set of criteria laid out by him. 
According to this author, a proof of causality requires 
the agent to be present in every case of a particular 
disease, to be absent in other diseases, and after isola-
tion and culture, be sufficient to reproduce the disease 
by inoculation of a susceptible host.
Since then, some modifications of these postulates have 
been proposed, including the following: the acknowledg-
ment of viruses as infectious agents (they were unknown 
in Koch’s time),7,19 of the importance of the study of anti-
bodies (presence and time of appearance),19 of the possi-
bility of disease prevention using vaccines against the 
virus, 10 of the importance of epidemiological studies,10 
and of the concept that several factors, and not only a 
single cause, can contribute to disease development.7
Owing to the advances in molecular biology tech-
niques, proposals to amend Koch’s postulates from 
the 80s onwards included criteria based on microbial 
genetics.9,13,16 Among these recent propositions, both 
the criteria of Mokili et al,16 based on the comparison 
of metagenomic characteristics among infected and 
healthy individuals, and the criteria of Lipkin,13 who 
grouped laboratory, clinical and epidemiological data 
into three certainty levels to establish an association 
between pathogens and diseases, considered the inocu-
lation of the infectious agent in a healthy individual as 
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a criterion for the confirmation of causality (this crite-
rion was inherited from Koch’s postulates). However, 
because of ethical issues, it is not possible to inoculate 
a suspected pathogen in human beings, and with excep-
tions such as the SARS-related human coronavirus, few 
etiological agents have a susceptible experimental animal 
model.2 Moreover, Lipkin13 suggested an alternative to 
this rule from Koch’s postulates and indicated that a 
causal association can be confirmed if the disease can be 
attenuated or prevented with the use of microorganism-
specific vaccines, drugs, or antibodies.
On the other hand, according to the molecular guide-
lines of Fredericks & Relman9 for establishing micro-
bial disease causation, there is no need to isolate a virus 
or inoculate it in a host. These guidelines are based 
on the identification of the microbial genome using in 
situ hybridization in tissue samples with pathological 
changes and on the analysis of the copy number of 
pathogen-associated nucleic acid sequences in tissue 
samples with or without lesions during several phases 
of the disease, including the period before disease onset.
Because of the difficulties encountered when applying 
the postulates of causality, it is accepted that not all 
criteria listed by authors need to be fulfilled.7,9-11,19 
In case it is impossible to fulfill all the criteria, the 
evidence accumulated over time and the common sense 
of researchers will be important to identify the causal 
agent of a certain disease.9,13,19
VIRAL METAGENOMICS
The term “metagenomics” indicates a joint analysis of 
microbial genomes in an environmental sample, not 
only from the genetic point of view but also in terms 
of function.18
The term “viral metagenomics” involves the detection 
of the genome of all viruses present in environmental 
samples (e.g., fresh water lake, reclaimed water),5,20 
or biological samples (e.g., respiratory tract aspirates, 
human and animal feces)14,17,28 that could harbor a 
large diversity of viruses. This term is also used when 
the metagenomic approach is applied to identify the 
genome of a virus that can potentially cause a specific 
disease and/or a cytopathic effect in cell culture, when 
other common techniques failed to detect the virus.24,30
The metagenomic approach includes several steps, as 
follows: the purification and concentration of the viral 
particles (or the viral nucleic acid if the virus is found 
in the latent form or integrated into the host genome), 
nucleic acid extraction, reverse transcription of RNA 
to cDNA, random amplification of genomic sequences, 
sequencing of nucleic acid fragments, and sequence 
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analysis using bioinformatics tools.2,12,27 Nucleic 
acid fragments can be sequenced using the Sanger 
method after molecular cloning or using next-gener-
ation sequencing platforms, which are more sensitive 
and generate a much larger number of sequences than 
molecular cloning using a bacterial host.2,12,16,27
DISCOVERY OF VIRUSES THROUGH VIRAL 
METAGENOMICS
Although the metagenomic approach has been signifi-
cantly contributing to the tremendous increase in the 
discovery of viruses,16 the number of novel associations 
between viruses and diseases has not been increasing 
in the same proportion. The causal association depends 
not only on detecting the presence of a virus in a sick 
person but also on conducting a complete investiga-
tion of the virus-disease association in order to comply 
with Koch’s postulates or with the criteria of causation 
proposed later.
 The use of the metagenomic approach in environmental 
samples has enabled the discovery of several novel 
genomic sequences potentially derived from viruses. 
However, the data obtained from these genomes are 
insufficient to identify the hosts and assess the patho-
genic potential of the viruses. Cataloging these genomes 
into public databases is important, so that after further 
research, it will hopefully be possible to identify the 
viral hosts.
The need to identify the correct host and the potential 
pathogenicity of the virus is also imperative when a 
previously unknown virus is found in fecal samples 
or upper respiratory tract secretions. The presence of 
a virus in these samples during the acute phase of the 
disease does not necessarily make this agent respon-
sible for the pathology. This can be the case when a 
virus shedded from the host for a prolonged period, 
e.g., enterovirus and bocavirus, is detected.29 In addi-
tion, a virus detected in fecal samples or respiratory 
tract secretions may have been inhaled or ingested and 
may have passed through the lumen of the respiratory 
or digestive tract without replicating into that host.3,12 
The human bocavirus exemplifies the difficulty in 
evaluating the causal association between a newly 
discovered virus in the respiratory tract and the clinical 
manifestations. Bocaviruses were discovered in 2005 
using a metagenomic approach in a pool of randomly 
selected samples of nasopharyngeal aspirates1 and 
have been a topic of intense research since then. This 
research has indicated that the factors that hinder 
the establishment of a causal association between 
the virus and disease include the high prevalence of 
bocavirus infection, prolonged viral shedding by the 
host after infection, persistence of the viral DNA in 
the respiratory tract for several months, and high rate 
of coinfection. The studies conducted to date suggest 
that bocaviruses are sometimes transient passengers 
and eventually pathogens of the respiratory tract.4,29
Even when the metagenomic approach leads to the 
detection of a new virus in the cerebrospinal fluid 
(CSF), which is generally sterile, the disease cannot be 
associated with the virus before further investigation.26 
This hypothesis can be discussed on the basis of recent 
findings of Tan et al,26 who found a new cyclovirus in 
CSF specimens of two patients with an acute infection 
of the central nervous system. After its identification, 
this virus was detected in 4.0% of 642 CSF samples 
from patients suspected of having an infection of the 
central nervous system; however, it was not detected 
in any of the 122 samples from patients with a nonin-
fectious neurologic disease. The viral genome was 
also found in fecal samples of healthy children, which 
suggested food-borne or fecal-oral transmission route. 
In addition, it was found in animal feces, suggesting 
the existence of animal reservoirs for this virus. These 
authors affirmed that, considering the current knowl-
edge, it is impossible to establish a causal association 
between this virus and the disease according to Koch’s 
criteria or their adapted versions. For further assess-
ment of this association, Tan et al26 are attempting to 
isolate the virus in cell cultures or animal models and 
to detect a specific immune response. This is a justi-
fiable caution because a virus found in CSF can be a 
coinfectious agent – which would play a secondary 
role in disease pathology and could increase disease 
severity or facilitate the entry of other pathogens –, or 
a latent virus that was reactivated because of an infec-
tious/inflammatory process, or it can simply reflect 
the detection of a latent virus.6,22,23,26 This discussion is 
common in cases of detection in CSF of human herpes-
viruses that are disseminated through the hematogenous 
route, such as the Epstein-Barr virus and the human 
herpesvirus 6.6,22,23 The new cyclovirus could also be 
like the anelloviruses, which establish chronic active 
infections, may be devoid of pathogenicity (they can 
be components of the normal human microflora), and 
can be found in the central nervous system, blood, and 
several other body fluids.15
The viruses can also be detected by metagenomic 
approaches in chronic diseases; however, the causal 
association can be even more difficult,27 as can be 
observed in a large amount of data on the Merkel cell 
polyomavirus (MCV). This virus was identified in 
human Merkel cell carcinoma (MCC) samples,8 and 
the investigation of the causal association between 
MCV and the disease began with the investigation of 
10 MCC samples from different patients; of these, the 
viral genome was detected in eight samples. In 75.0% 
of these samples, viral DNA was integrated into the 
tumor genome in a clonal pattern, suggesting that the 
infection and integration process preceded the clonal 
expansion of the tumor cells. Control tissue samples 
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tested positive for the MCV genome in expressively 
lower percentage, and there was evidence that the 
number of copies of the viral genome in these positive 
samples was lower than that in the MCC samples.8 A 
high incidence of MCV among MCC cases has been 
confirmed in several countries, except in Australia.21 It 
is known that human infection with MCV occurs early, 
considering that the seroprevalence is 50.0% among 
individuals aged below 15 years.21 Studies with RNA 
interference and on the genetic changes of the viral 
genome integrated into MCC cells have indicated that 
MCV may contribute to the onset of MCC.21
When a new virus is detected in the blood of a patient 
with a disease that is probably infectious, only the 
identification of a new agent is also not proof of its 
causal relationship with the disease, as can be exem-
plified by the discovery of a new bunyavirus in China, 
which was named Henan fever (HNF) virus30 or 
severe fever with thrombocytopenia syndrome virus 
(SFTSV).31 This virus was detected almost simulta-
neously by two research groups using a metagenomic 
approach in serum30 and blood leucocytes;31 samples 
were obtained during the acute phase of the disease, 
which is characterized by fever, thrombocytopenia, 
and leukopenia. An extensive epidemiological, clinical, 
and laboratory investigation was conducted along with 
this discovery. In the laboratory, the evidence for this 
association included viral isolation, followed by visu-
alization of the viral particles by electron microscopy, 
detection of the viral genome, and positive serology in 
patient samples.30,31 The investigation by both research 
groups also included analysis of the control groups. 
When discussing the causal association between the 
HNF virus and the severe fever with thrombocytopenia 
syndrome, both the groups concluded that, although 
they could not completely fulfill Koch’s postulates, 
there was a strong evidence indicative of this asso-
ciation.30,31 The fact that independent researchers 
confirmed these results25,30,31 corroborates this potential 
association, as stated in Lipkin’s guidelines.13
FINAL CONSIDERATIONS
Viral metagenomics has been having a great impact 
on the discovery of new viruses because it enables 
the detection of all viral genomes present in a given 
sample independently from antisera tests, from previous 
knowledge of the viral genome (unlike other molecular 
biology techniques such as polymerase chain reaction, 
microarray, and in situ hybridization), and from cell 
culture isolation.2,16,27
However, the causal association between a virus and 
a disease in humans and other animals still depends 
on a set of clinical, epidemiological, and laboratory 
investigations; on the use of strict criteria to associate 
these elements, such as those in Koch’s postulates and 
their adapted versions; and on common sense during 
data analysis.9,10,12,13,16,19
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